Overview

Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome

Status:
Unknown status

Trial end date:
2017-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of 5mg maintenance dose (MD) of prasugrel in patients with acute myocardial infarction (AMI) who underwent percutaneous coronary intervention (PCI) with BiomatrixTM stent.

Phase:

Phase 4

Details

Lead Sponsor:

Chonnam National University Hospital

Treatments:

Clopidogrel
Prasugrel Hydrochloride